Introduction
Medulloblastoma is a malignant invasive tumor of the cerebellum representing one of the most common neoplasms of the nervous system in children (Farwell et al., 1984) . While a small percentage of these embryonal neuroblastic tumors are related to genetically de®ned heritable syndromes associated with a predisposition toward tumorigenesis, the majority of medulloblastomas are sporadic and their etiology remains unknown. Loss of heterozygosity in portions of chromosome seventeen (17p) seen in 30 to 45% of medulloblastomas (Cogen and McDonald, 1996) led to the early speculation that the tumor suppressor protein, p53, may play a key role in the development of medulloblastomas. Although p53 has been shown not to be mutated.
Recently, we have developed a transgenic animal model using the early genome of the human JC virus (JCV) which contains the viral early promoter encoding the oncogenic protein, JCV T-antigen (Krynska et al., 1999) . JCV, a neurotropic polyomavirus, is an established etiologic agent of Progressive Multifocal Leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system (CNS) (Berger and Concha, 1995; Major et al., 1992) . JCV co-exists within the human population, as greater than 80% of adults worldwide exhibit JCV-speci®c antibody (Taguchi et al., 1982; Walker and Padgett, 1983) . Examination of the central nervous system (CNS) of transgenic animals revealed no features of hypomyelination or abdominal tumors of neuroblastoma origin, two distinct pathologies which were reported upon expression of JCV T-antigen in brain (Franks et al., 1996; Small et al., 1986a,b) . However, mice which contained neurological disorders, developed cerebellum tumors which closely parallel human medulloblastomas in location, histological appearance, and expression of dierentiation markers.
Cell lines derived from JCV-induced medulloblastoma in transgenic mice can be divided into two groups based on their level of T-antigen expression. The Tantigen positive cells, which have retained their neural characteristics, grow rapidly in cell culture, and induce large tumors in¯anks of nude mice. The Tantigen negative cells, on the other hand, which also maintain their neural features, possess a slower growth rate and form signi®cantly smaller size tumors in mice (Krynska et al., 2000) . Since in both cell types, the p53 tumor suppressor is non-functional, either due to its association with T-antigen or the presence of a mutation in exon 4, the dierences in the growth rate and tumorigenicity of these two cell types may not be entirely attributable to the p53 pathway. Therefore, alternative pathways not involving p53 may also be aected by T-antigen and contribute to the oncogenecity of T-antigen. Indeed, one may envision that JCV T-antigen, by interacting with the Rb family of tumor suppressors, potentiates several factors such as E2F-1 and cyclins, and thus, stimulates cell growth (Paggi et al., 1996) . In fact, earlier studies on glioblastoma cell lines derived from brain tumors induced upon intracerebral injection of JCV in newborn hamsters showed that the interaction of JCV T-antigen with pRb2 may have a functional consequence which leads to uncontrolled cell growth in animal system (Howard et al., 2000) . While the functional importance of the Rb family of tumor suppressors in the development of medulloblastoma remains unknown, our previous studies have revealed that in mouse medulloblastoma, the T-antigen of JCV can be found in a complex with pRb (Krynska et al., 1999) . This is an important observation in light of recent in vivo studies showing that inactivation of pRb in p53 null mice can induce tumors from the external granular layer of the cerebellum which includes medulloblastoma (Marino et al., 2000) . Thus, multiple pathways, which include the inactivation of tumor suppressors, may be involved in the genesis of medulloblastomas.
Other pathways which may be involved in the development of these cerebellar neoplasia include the b-catenin signaling or Wnt pathway. The signaling activity of b-catenin is controlled via its interaction with LEF-1/TCF family of transcription factors and subsequent activation of the target genes including cmyc and cyclin d1 (Morin, 1999) . Stabilization of bcatenin by a variety of mechanisms such as mutation in serine and threonine residues of its exon 3, which prevents its phosphorylation by glycogene synthase kinase 3 (GSK3), enables cytoplasmic b-catenin to associate with LEF-1/TCF and more eciently enter the nuclei to stimulate transcription from its target genes. In previous studies, b-catenin was observed in the nuclei of human medulloblastomas and mutations in the residues that aect the phosphorylation site of the protein and its stability were detected (Eberhart et al., 2000) . These observations suggest a potential role for b-catenin signaling in medulloblastoma. Our results presented here demonstrate activation of b-catenin in T-antigen positive but not T-antigen negative tumor cells. Our ®ndings also indicate that enhanced level of b-catenin and its partner LEF-1 in nuclei are consistent with an enhanced level of c-myc gene expression.
Results and Discussion
Examination of b-catenin production and its subcellular localization revealed that in T-antigen positive cells, bcatenin is detected in both nuclei and cytoplasm. Figure  1 illustrates nuclear staining of T-antigen positive cells with anti-T-antigen antibody (a) and cytoplasmic and nuclear reactivity of these cells for b-catenin antibody (b). In T-antigen negative cells, which show no evidence for T-antigen immunoreactivity (c), b-catenin was found only in the perinuclear area of the cytoplasm (d).
In the next series of experiments, we examined the level of b-catenin and LEF-1 expression in T-antigen positive and T-antigen negative mouse medulloblastoma cell lines. As shown in Figure To investigate the association of LEF-1 from Tantigen positive and T-antigen negative with the DNA fragment containing the LEF-1 binding site, we performed DNA mobility shift experiments. In this study, approximately 10 mg of nuclear extract from Tantigen negative and T-antigen positive cells were prepared and incubated with a 32 P-labeled DNA probe containing the LEF-1 binding site. As shown in Figure  3a , the association of nuclear protein with the DNA probe resulted in the formation of a complex which disappeared upon inclusion of an unlabeled DNA fragment containing the LEF-1 binding site but not a mutant DNA competitor (compare lane 1 with lanes 2 and 3, and lane 4 with lanes 5 and 6). Interestingly, under similar conditions, the intensity of the band corresponding to the LEF-1 DNA protein complex was signi®cantly higher in T-antigen positive cells than in T-antigen negative cells.
To further illustrate the association of LEF-1 in the DNA protein complex, anti-LEF-1 antibody was included in the DNA binding reaction. As shown in Figure 3b , incubation of the DNA probe with extract from T-antigen positive cells resulted in the formation of a nuclear protein complex which, in the presence of anti-LEF-1 antibody, was supershifted, indicating the presence of LEF-1 in the complex (compare lane 1 with lane 2). Inclusion of anti-b-catenin or control serum had no eect on the electrophoretic mobility of the complexes (lanes 3 and 5) indicating the speci®city of the observed event. Curiously, we found an enhancement in the intensity of the band upon inclusion of anti-b-catenin to the binding reaction. Further, the addition of both anti-LEF-1 and anti-b-catenin antibodies to the binding reaction completely abrogated the appearance of the band (lane 4) suggesting that either the complex became very large and did not enter the gel or the two antibodies work together to block the DNA binding site of LEF-1. These observations altogether provide evidence for an enhanced level of LEF-1 in T-antigen positive medulloblastoma cells, and the ability of LEF-1 to interact with its DNA target.
As mentioned earlier, one of the target genes for LEF-1 stimulation is c-myc whose upregulation can lead to uncontrolled cell growth and proliferation. As such, in the next series of experiments, we examined the level of c-myc gene expression by Northern and Western blot analyses. As shown in Figure 4a , the intensity of the band corresponding to c-myc was noticeably higher in T-antigen positive cells (Figure 4a, top) , suggesting (Figure 4a, bottom) . Results from Western blot analysis further con®rm the above observation and demonstrated higher levels of c-myc protein production in T-antigen positive versus T-antigen negative cells (Figure 4b, top) . Again, no dierence in the level of Grb-2 production was observed in this experiment (Figure 4b, bottom) . These data, altogether, demonstrate that expression of T-antigen may cause upregulation of c-myc in medulloblastoma cells.
To directly demonstrate the eect of T-antigen on transcriptional activation of the c-myc promoter we performed co-transfection experiments in T-antigen negative and T-antigen positive cells. In these studies, cells were transfected with a DNA plasmid containing the c-myc promoter transcribing the reporter Luciferase gene, either alone or together with the JCV T-antigen expression plasmid. As shown in Figure 5a , ectopic expression of T-antigen in T-antigen negative cells caused an increase in the level of c-myc promoter activity (Figure 5a) . Similarly, enforced expression of T-antigen in T-antigen positive cells enhanced c-myc transcription in these cells (Figure 5b ). It should be noted that under similar conditions the basal level of cmyc promoter activity was slightly higher in T-antigen positive than in T-antigen negative cells (compare ®rst lanes in Figure 5a and b) suggesting that endogenous production of T-antigen in T-antigen positive cells contributes to the higher level of c-myc gene transcription in these cells.
In the reciprocal experiments, we investigated the eect of c-myc on transcription of the JCV early promoter in T-antigen negative cells. Results from transfection studies revealed that ectopic expression of c-myc results in down-regulation of JCV early promoter activity (Figure 5c ). Similar to other polyomaviruses, JCV T-antigen has the ability to autoregulate its transcriptional activity. As shown in Figure 5c , production of JCV T-antigen results in a decrease in the level of transcription from the JCV early promoter. Under this condition, c-myc only marginally reduced JCV early gene transcription, suggesting that cooperativity between T-antigen and c-myc may dictate the level of JCV early gene transcription in these cells.
The T-antigen of the human neurotropic virus, JCV, has oncogenic activity (Gallia et al., 1998) which is attributed, at least in part, to its ability to interact with several tumor suppressor proteins and interferes with their cell growth inhibitory functions Krynska et al., 1997) . The ability of polyomavirus T-antigen to associate with and functionally inactivate p53 (May and May, 1999) suggests a potential role for p53 in uncontrolled cell proliferation and predisposition to neoplasia in the mouse model of medulloblastoma. To further examine the mechanism involved in the induction of medulloblastoma by Tantigen, clonal cell lines were derived from the mouse medulloblastoma. While a majority of tumor cells produced T-antigen, there exist some tumor cells with no evidence of T-antigen expression (Gordon, J., unpublished observations; Krynska et al., 2000) . Examination of p53 expression in T-antigen positive and T-antigen negative tumor cell lines revealed that wild-type p53 is produced in T-antigen positive cells and is found in association with T-antigen. In Tantigen negative cells, p53 was found to be mutated with a deletion that removes residues between 35 to 123. Examination of the T-antigen negative cells which have a p53 mutation showed decreases in both their level of proliferation in vitro as well as their ability to form large tumors in nude mice compared to T-antigen positive medulloblastoma cells. These observations suggested that in addition to p53, other regulatory pathways which are aected by T-antigen may be involved in the development of mouse medulloblastoma. In light of earlier observations on the detection of mutations in the b-catenin gene from human medulloblastoma (Eberhart et al., 2000) , and the role of Wnt signaling in the control of neural crest cell fate (Cadigan and Nusse, 1997; Dorsky et al., 1998) , we focused our attention on studying the Wnt signaling pathway in T-antigen positive and T-antigen negative cells. b-catenin is a cytoplasmic protein which associates with cadherin and couples these calciumdependent membrane-bound adhesion molecules to components of the cytoskeleton (Aberle et al., 1996; HuÈ lsken et al., 1994; Jou et al., 1995; Moon et al., 1997; Peifer 1995) . In addition, the association of free catenin with glycogen synthase kinase 3b (GST-3b) results in rapid degradation of free b-catenin in the cytoplasm (Miller et al., 1999) . Somatic mutation in APC which typically leads to a truncated protein with no regulatory activity can cause the accumulation of free b-catenin. A mutation in b-catenin increases its half-life and permits this protein to associate with the transcription factor LEF-1, and be translocated to nuclei. Following translocation to the nucleus, bcatenin nuclear interacts with speci®c DNA sequences (5'-CCTTTGAACT-3') positioned in the promoter of WNT-responsive genes (Behrens et al., 1996) including cell cycle regulators such as c-myc and cyclin D, and stimulates their transcription.
Results from co-transfection studies show that JCV T-antigen can stimulate transcription of the c-myc promoter in tumor cells. Further, from these studies it appears that while c-myc suppresses the JCV early promoter, it has no signi®cant in¯uence on the level of JCV early promoter activity in the presence of the viral early protein. This observation suggests that the functional interaction between T-antigen and c-myc may play a role in orchestrating c-myc proliferative activity in these cells. While the mechanism by which T-antigen-mediated stimulation of the c-myc promoter remains unknown, one may speculate that the association of T-antigen with b-catenin and/or LEF-1 may result in the stabilization of this protein and facilitate its nuclear import where it can stimulate cmyc promoter transcription. In support of this model, our most recent preliminary GST pull-down assay has provided evidence for the direct interaction of Tantigen with both b-catenin and LEF-1 (Dai-Di Gan, unpublished observations). JCV has recently been shown to be associated with signi®cant numbers of human medulloblastomas. According to one model, it is possible that expression of T-antigen in the external granular layer of the cerebellum results in de-regulation of the b-catenin pathway by interacting with b-catenin and LEF-1 and altering their subcellular localization. Further studies of b-catenin expression in clinical samples expressing T-antigen should provide insight into the pathogenesis of medulloblastoma and the interplay of b-catenin and T-antigen in the development of pediatric malignancies.
